Q-omics provides the consensus-scored CORO6 profile across patient tissues and cancer cell-line models. CORO6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CORO6 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, CORO6 RNA expression shows 22,727 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where CORO6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORO6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORO6 survival associations across molecular data types. CORO6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORO6 RNA expression–survival associations across cancer types. High CORO6 expression shows unfavorable associations in KIRC, UVM, COAD, ACC, UCEC and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CORO6 RNA expression.
This table summarizes CORO6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CORO6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORO6 shows lower tumor expression in BLCA, STAD, COAD and UCEC and higher tumor expression in KIRP and LUSC. The BLCA box plot shows higher CORO6 RNA expression in normal versus tumor tissue (log2 FC = −2.345, t-test p = .001).
This table shows molecular features associated with CORO6 in patient tissues and cancer cell lines. In patient samples, CORO6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CORO6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
